Data Year:

For its 2025 fiscal year, WEST PHARMACEUTICAL SERVICES INC, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2025
Name And Title Total Compensation Pay Rank By Title In MFG Durable industry
Eric M. Green
President and CEO, Chair of Board
Total Compensation $7,143,071 View details Pay Rank By Title In MFG Durable industry #318 View more
Annette F. Favorite
SVP, Chief Human Resources Officer
Total Compensation $1,384,913 View details Pay Rank By Title In MFG Durable industry #31 View more
Bernard J. Birkett
Former SVP, Chief Financial Officer
Total Compensation $2,143,249 View details Pay Rank By Title In MFG Durable industry #365 View more
Kimberly B. MacKay
Former SVP, General Counsel and Secretary
Total Compensation $1,258,170 View details Pay Rank By Title In MFG Durable industry #154 View more
Robert W. McMahon
SVP, Chief Financial Officer
Total Compensation $11,804,963 View details Pay Rank By Title In MFG Durable industry #21 View more
Shane A. Campbell
SVP, Chief Proprietary Segment Officer
Total Compensation $2,402,998 View details Pay Rank By Title In MFG Durable industry #90 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at WEST PHARMACEUTICAL SERVICES INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. WEST PHARMACEUTICAL SERVICES INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. WEST PHARMACEUTICAL SERVICES INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Eric M. Green
President and CEO, Chair of Board
Total Cash $2,648,903 Equity $4,436,009 Other $58,159 $7,143,071
Annette F. Favorite
SVP, Chief Human Resources Officer
Total Cash $898,590 Equity $457,066 Other $29,257 $1,384,913
Bernard J. Birkett
Former SVP, Chief Financial Officer
Total Cash $637,808 Equity $1,468,155 Other $37,286 $2,143,249
Kimberly B. MacKay
Former SVP, General Counsel and Secretary
Total Cash $803,550 Equity $424,255 Other $30,365 $1,258,170
Robert W. McMahon
SVP, Chief Financial Officer
Total Cash $3,810,676 Equity $7,309,344 Other $684,943 $11,804,963
Shane A. Campbell
SVP, Chief Proprietary Segment Officer
Total Cash $924,911 Equity $1,453,164 Other $24,923 $2,402,998
For its 2025 fiscal year, WEST PHARMACEUTICAL SERVICES INC, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Eric M. Green CEO Pay $7,190,876 Median Employee Pay $64,635 CEO Pay Ratio 111:1
For its 2025 fiscal year, WEST PHARMACEUTICAL SERVICES INC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Deborah L. V. Keller Total Cash $334,941
Douglas A. Michels Total Cash $329,941
Janet B. Haugen Total Cash $330,941
Mark A. Buthman Total Cash $344,941
Molly E. Joseph Total Cash $343,842
Myla P. Lai-Goldman Total Cash $344,941
Paolo Pucci Total Cash $332,139
Robert F. Friel Total Cash $353,842
Stephen H. Lockhart Total Cash $329,941
Thomas W. Hofmann Total Cash $355,941
William F. Feehery Total Cash $329,941
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.